UCB Announces New Results From Phase 2b Open-Label Extension Study Evaluating The Long-Term Effects Of Epratuzumab In SLE

UCB have announced new data from an open-label extension (SL0008) of the EMBLEM™ phase 2b study evaluating the long-term effects of epratuzumab treatment in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). The primary outcome of the open-label extension was to assess the safety of epratuzumab in patients with SLE.4 Relative to the 12 week, double-blind, placebo-controlled EMBLEM™ study, data from the open-label, long-term extension identified no new safety or tolerability signals...

Source: Health News from Medical News Today - June 15, 2013 Category: Consumer Health News Tags: Lupus Source Type: news